Evaluation of ICP-B381 in Patients With Advanced Solid Tumors
An Open, Multicenter, Phase I/II Study to Evaluate the Safety, Tolerability, Pharmacokinetics Characteristics, and Efficacy of ICP-B381 in Participants With Advanced Solid Tumors
To evaluate the safety, tolerability, efficacy and pharmacokinetic characteristics of ICP-B381 in the trial participants of advanced solid tumors
Studieoversigt
Status
Status
Betingelser
Betingelser
Intervention / Behandling
Intervention / Behandling
Undersøgelsestype
Undersøgelsestype
Tilmelding (Anslået)
Tilmelding
Fase
Fase
- Fase 2
- Fase 1
Kontakter og lokationer
Studiekontakt
Studiekontakt
- Navn: Jingnan Yang
- Telefonnummer: 010-66609990
- E-mail: CO-Clinicaltrial@innocarepharma.com
Studiesteder
-
-
Shanghai Municipality
-
Shanghai, Shanghai Municipality, Kina, 200032
- Rekruttering
- Fudan University Shanghai Cancer Center
-
Kontakt:
- DingWei Ye, M.D.
- Telefonnummer: 021-64175590*81807
- E-mail: dwyeli@163.com
-
-
Deltagelseskriterier
Berettigelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- Participants must be at least 18 years old.
- Participants thoroughly understand study procedures, and voluntarily sign the written ICF
- Eastern Cooperative Oncology Group (ECOG) performance status score 0-1.
- Expected survival time ≥3 months.
- Histopathologically confirmed metastatic castration-resistant prostate cancer (mCRPC) & Other advanced solid tumor
- Agree to provide FFPE slides from archived tumor tissues collected within the past 2 years or fresh tumor biopsies (for archived samples, more recently collected specimens are preferred
- The organ function level must meet the prescribed standards
- All toxicities derived from previous anti-neoplasm treatments must have been resolved to Grade ≤1 (per CTCAE V6.0)
- Effective contraceptive measures should be taken from the date of signing the informed consent form until at least 6 months after the use of the last dose of the study drug
- Female participant of childbearing potential must have a negative blood pregnancy test at the screening visit
- Female participants must not breastfeed or plan pregnancy during the study and for at least 6 months after the last dose.
- Participants can communicate well with the Investigator and can complete the study according to the study protocol
Exclusion Criteria:
- Other active malignant tumors occurred within 3 years before the first administration of the study drug
- Has previously received or is currently receiving the same type of drug or related treatment as stipulated in the protocol
- Has a previous medical history and adverse life history as specified in the protocol, or has a disease as specified in the protocol
- Has received cytotoxic chemotherapy, radical radiotherapy, molecular targeted therapy, immunotherapy, anti-tumor vaccine therapy, cytokine therapy, or other investigational anti-cancer drugs with an elution time not meeting the protocol requirements
- Had active bleeding within 2 months before screening or had clinically significant or significant bleeding tendency, or was experiencing bleeding symptoms due to taking anticoagulant drugs or other medical interventions
- Had major surgery within 28 days before the first administration or minor surgery within 2 weeks before the first administration
- Has received systemic immunosuppressive drugs as stipulated in the protocol for 14 days before the first administration
- Has a history of severe allergic reactions to the active ingredient, non-active ingredients in the drug, or antibody-based drugs
- Had the first administration within 2 weeks before or is planned to use drugs or foods with strong inhibitory or inducing effects on cytochrome P450 CYP3A before the study
- Has any mental or cognitive disorders that may limit their understanding, execution of the informed consent form, and compliance with the study
- Situations that the investigator deems unsuitable for participating in this study
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: N/A
- Interventionel model: Sekventiel tildeling
- Maskning: Ingen (Åben etiket)
Antal våben
Våben og indgreb
Deltagergruppe / ArmDeltagergruppe / Arm |
Intervention / BehandlingIntervention / Behandling |
|---|---|
|
Eksperimentel: ICP-B381
|
ICP-B381 will be administered by intravenous infusion every 3 weeks (Q3W) until disease progression (PD) or the occurrence of unacceptable toxicity or withdrawal from the study for other reasons (whichever occurs first). |
Hvad måler undersøgelsen?
Primære resultatmål
Primære resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
The type, severity (assessed according to the National Cancer Institute Common Terminology Criteria for Adverse Events version 6.0 [NCI-CTCAE V6.0]), relationship to the investigational product, and incidence rate of adverse event (AE) and serious advers
Tidsramme: 2 years
|
2 years
|
|
The type, severity (assessed according to NCI-CTCAE V6.0), and incidence rate of dose limiting toxicity (DLT)
Tidsramme: 2 years
|
2 years
|
|
Single-agent Recommended Dose (RD) and/or Maximum Tolerated Dose (MTD)
Tidsramme: 2 years
|
2 years
|
|
Participants with prostate cancer: Prostate-specific antigen (PSA50) response rate
Tidsramme: 2 years
|
2 years
|
|
Participants with other tumor types: Investigator-assessed Objective response rate (ORR)
Tidsramme: 2 years
|
2 years
|
|
The optimal dosing regimen for the subsequent study of ICP-B381
Tidsramme: 2 years
|
2 years
|
Sekundære resultatmål
Sekundære resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
Samlet overlevelse (OS)
Tidsramme: 2 år
|
2 år
|
|
Varighed af svar (DOR)
Tidsramme: 2 år
|
2 år
|
|
Objektiv svarprocent (ORR)
Tidsramme: 2 år
|
2 år
|
|
Maksimal koncentration (Cmax)
Tidsramme: 2 år
|
2 år
|
|
Disease Control Rate (DCR)
Tidsramme: 2 år
|
2 år
|
|
Time to Maximum Plasma Concentration (Tmax)
Tidsramme: 2 years
|
2 years
|
|
Half-life (T1/2)
Tidsramme: 2 years
|
2 years
|
|
Area Under the Serum or Plasma Concentration-Time Curve (AUC0-∞ and AUC0-t)
Tidsramme: 2 years
|
2 years
|
|
Apparent Clearance Rate (CL/F)
Tidsramme: 2 years
|
2 years
|
|
Terminal Apparent Volume of Distribution (Vz/F)
Tidsramme: 2 years
|
2 years
|
|
Steady-state Pharmacokinetic Parameters
Tidsramme: 2 years
|
2 years
|
|
Participants with prostate cancer: radiographic progression-free survival (rPFS) evaluated by the Investigator according to RECIST V1.1 criteria (for soft tissue lesions) and PCWG3 criteria (for bone lesions)
Tidsramme: 2 years
|
2 years
|
|
Participants with prostate cancer: changes in serum PSA levels compared to baseline during the study: PSA50 response rate
Tidsramme: 2 years
|
2 years
|
|
Participants with prostate cancer: PSA90 response rate
Tidsramme: 2 years
|
2 years
|
|
Participants with prostate cancer:12-week PSA response rate
Tidsramme: 2 years
|
2 years
|
|
Participants with prostate cancer: time to PSA progression (TTPP)
Tidsramme: 2 years
|
2 years
|
|
Time to First Subsequent Therapy (TFST)
Tidsramme: 2 years
|
2 years
|
|
Participants with prostate cancer: incidence rate of symptomatic skeletal event (SSE)
Tidsramme: 2 years
|
2 years
|
|
Participants with prostate cancer: time to first symptomatic skeletal event (TTSSE)
Tidsramme: 2 years
|
2 years
|
|
Incidence rate of anti-drug antibody (ADA) against ICP-B381
Tidsramme: 2 years
|
2 years
|
|
Types, severity (assessed according to NCI-CTCAE V6.0), relationship with the investigational product, and incidence rate of AE and SAE
Tidsramme: 2 years
|
2 years
|
Samarbejdspartnere og efterforskere
Sponsor
Sponsor
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Studiestart
Primær færdiggørelse (Anslået)
Primær færdiggørelse
Studieafslutning (Anslået)
Studieafslutning
Datoer for studieregistrering
Først indsendt
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Først opslået
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering sendt
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Andre undersøgelses-id-numre
Andre undersøgelses-id-numre
- ICP-CL-01901
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .